SCHEMBL1272687

SCHEMBL1272687

CS(=O)(=O)Cc1nc(-c2ccccc2)no1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.58
▸ TSHR P16473 6/20 0.56
▸ MAPT P10636 5/20 0.56
▸ MAPK1 P28482 4/20 0.56
▸ HTT P42858 2/20 0.56
▸ NPC1 O15118 6/20 0.55
▸ RAB9A P51151 6/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ TDP1 Q9NUW8 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ HTR1A P08908 1/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.52
▸ THRB P10828 1/20 0.50
▸ CASP3 P42574 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1272686 0.84 NOTUM (0.58) NOTUMTSHRMAPTMAPK1HTT
SCHEMBL2070164 0.83 MAPT (0.58) NOTUMTSHRMAPTMAPK1HTT
SCHEMBL91541 0.78 NOTUM (0.68) NOTUMTSHRMAPTMAPK1NPC1
SCHEMBL2089284 0.78 NOTUM (0.68) NOTUMTSHRMAPTMAPK1NPC1
SCHEMBL9087479 0.76 MAPT (0.52) TSHRMAPTMAPK1HTTNPC1
SCHEMBL27962964 0.75 NR1H4 (0.53) NOTUMTSHRMAPTMAPK1HTT
SCHEMBL14288613 0.75 RAB9A (0.70) NOTUMTSHRMAPTMAPK1HTT
SCHEMBL14339592 0.75 NOTUM (0.64) NOTUMTSHRMAPTMAPK1HTT
SCHEMBL9830088 0.74 NOTUM (0.63) NOTUMTSHRMAPTMAPK1HTT
SCHEMBL17595755 0.74 NOTUM (1.00) NOTUMTSHRMAPTMAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1865940-B1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2013-02-13 — — EP disclosed
EP-2511257-A2 Alpha ketoamide compounds as cysteine protease inhibitors ViroBay, Inc. (US) 2012-10-17 — — EP disclosed
US-8013183-B2 Alpha ketoamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2011-09-06 — — US disclosed
US-7893093-B2 Sulfonyl containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2011-02-22 — — US disclosed
US-20100305331-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2010-12-02 — — US disclosed
US-20080287446-A1 Sulfonyl Containing Compounds as Cysteine Protease Inhibitors QUEST DIAGNOSTICS INVESTMENTS LLC 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287446-A1 Sulfonyl Containing Compounds as Cysteine Protease Inhibitors CTSS, CTSF, CTSB NOTUM 416/4885TSHR 4135/4885MAPT 3810/4885
US-20100305331-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSS, CTSF, CTSB NOTUM 359/4885TSHR 4642/4885MAPT 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback